Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-05-16 00:00:00 ET · period of report 2024-05-14 · accession 0000914475-24-000123 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-16 | 2024-05-14 | NBIX | LYONS GARY A | Dir | S - Sale+OE | $135.63 | -12.5K | 116.9K | -10% | -$1.70M |
| D | 2024-05-16 | 2024-05-14 | NBIX | LYONS GARY A | Dir | M - OptEx | $42.76 | +12.5K | 129.4K | +11% | +$534.5K |
| D | 2024-05-16 | 2024-05-14 | NBIX | LYONS GARY A | Dir | M - OptEx | $42.76 | -12.5K | 12.5K | -50% | -$534.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-14 | S | D | 12,500 | $135.63 | 116,947 | D | — | — | (F4) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $134.78 to $137.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F2) 110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. |
| 2 | Common | Common Stock | 2024-05-14 | M | A | 12,500 | $42.76 | 129,447 | D | — | — | (F1) Reflects a decrease of 76,750 shares from the amount previously reported as beneficially owned, which was recently discovered to be overstated due to an administrative oversight. (F2) 110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. |
| 3 | Derivative | Non-Qualified Stock Option | 2024-05-14 | M | D | 12,500 | $42.76 | 12,500 | D | $42.76 · — to 2025-05-28 | 12,500 Common Stock | (F5) The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025. |